Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Gastrointestinal 3Other hematologic neoplasm 2Dermatologic 2Breast 2Thoracic 1Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Endocrine 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 36Melphalan 29Cyclophosphamide 28Specimen Handling 26Biopsy 26Bortezomib 24Calcium Dobesilate 20Magnetic Resonance Spectroscopy 19Lenalidomide 17fludarabine phosphate 15Filgrastim 15Peripheral Blood Stem Cell Transplantation 13Vincristine 12Prednisone 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11carfilzomib 10Doxorubicin 10sargramostim 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6ixazomib 6Rituximab 6Etoposide 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Biological Therapy × Plasma cell × Clear all
NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡